The probiotic Bifidobacterium longum NCC3001 (BL) has beneficial effects in patients with irritable bowel disease (IBS), reducing depression but not anxiety scores and improving quality of life, a study has shown.
Use of varenicline and bupropion, medication to help quit smoking, is unlikely to be associated with increased risks of cardiovascular (CV) and neuropsychiatric adverse events compared with nicotine replacement therapy (NRT) in smokers with chronic obstructive pulmonary disease (COPD), in contrast to previous belief.
Patients with stable schizophrenia may benefit from long-term antipsychotic treatment, with a recent meta-analysis finding that continuation of antipsychotics over a 1-year period significantly reduces symptom exacerbation in this population in contrast to a trajectory of continuous symptom exacerbation in patients on placebo.
The norepinephrine transporter (SLC6A2, NET) variant rs2242446/T-182C shows potential as a biomarker to predict the possibility of remission with venlafaxine in older adults with major depression, a recent study has found.
Performance of moderate-intensity exercise lasting at least 15 minutes, three times a week, potentially lowers the risk of depressive symptoms in older adults, a study has found. Furthermore, increasing exercise frequency to more than five times per week will benefit this population both physically and psychologically.
Hearing loss is associated with an increased prevalence of dementia, according to a Singapore population-based study. Cognitively normal individuals with hearing loss have a twofold risk of developing neurocognitive disorders (mild cognitive impairment [MCI] or dementia).
New drug applications approved by US FDA as of 15 – 31 May 2015 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.